GSK 650394 Inhibits Osteoclasts Differentiation and Prevents Bone Loss via Promoting the Activities of Antioxidant Enzymes In Vitro and In Vivo

Figure 6

GSK suppresses bone loss of the ovariectomy mice in vivo. (a) Reconstruction of tibia using μCT for the sham mice, OVX with saline (vehicle), OVX with 10 mg/kg GSK (low dose), and with 30 mg/kg GSK (high dose) (b–g) Quantitative analysis of bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), connectivity density (Conn.Dn), and structure model index (SMI). (h) HE and TRAP staining were used to determine bone architecture and osteoclast activity, respectively (the black arrows represent osteoclasts), scale bar: 500/200 μm. (i–j) The counted number of osteoclasts per sections (N.Oc/BS) and the ratio of osteoclast surface/bone surface (Oc.S/BS). Data are presented as the (), ; ; ; .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)